Hansoo Kim Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Utility values across lines of therapy in immuno-oncology treatments: an example from advanced melanoma — Poster Session 1
• Cost effectiveness analysis (CEA) of nivolumab in 2nd line non-small cell lung cancer (NSCLC) with non-squamous histology (NSQ) using a mixed comparator of docetaxel and pemetrexed in an Australian setting — Poster Session 1
• Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia — Poster Session 1